ArticleAquaculture nutrition2025
The Promoting Effects of Fermented Bile Acid on Growth Performance and Intestinal Health of
Article in Aquaculture nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fermentation Technology in Aquafeeds: A Review.Microorganisms · 2026Review
- Comprehensive Analysis of Metabolome and Transcriptome Reveals Physiological Processes Related to Larval Development of Barnacles (Animals : an open access journal from MDPI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two types of bile acids (BAs), named fermented bile acids (FBAs) and 170HDa, were produced by a biological approach to assess their effects on growth performance, metabolism, and intestinal health in white shrimp. In this study, five experimental diets were prepared with varying levels of FBAs (0.02% for A1, 0.03% for A2, 0.04% for A3, 0.05% for A4, and 0.06% for A5) and five diets containing different concentrations of 170HDa (0.02% for B1, 0.03% for B2, 0.04% for B3, 0.05% for B4, and 0.06% for B5). Additionally, positive diets (P) with commercial BAs at a level of 0.04%, along with and negative diet (N) without BA supplementation, were included as controls. FBAs and 170HDa were found to improve the growth performance including final weight, weight gain, and specific growth rate and reduce the activities of aspartate aminotransferase and alanine aminotransferase in hemolymph. The alkaline phosphatase (AKP) activity of hemolymph in shrimp treated with FBAs was generally higher than in groups treated with 170HDa and the control groups. However, the acid phosphatase (ACP) activity of hemolymph in shrimp treated with FBAs showed similar levels to those treated with 170HDa and the control groups. The gene expression levels of antilipopolysaccharride factor (ALF) and proPO were significantly lower in most FBAs and 170HDa-treated groups compared to the control groups (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.